Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metabolic neuropathies

G Comi1, M Corbo

  • 1Department of Neurology, University of Milan, Scientific Institute H. San Raffaele, Italy.

Current Opinion in Neurology
|December 16, 1998
PubMed
Summary
This summary is machine-generated.

Diabetic neuropathy affects one-third of patients, with duration, poor control, smoking, and hypertension as key predictors. While no specific treatments exist, metabolic correction shows promise for nerve function improvement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

AJNR. American journal of neuroradiology·2011
Same author

Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

AJNR. American journal of neuroradiology·2011
Same author

Cortical lesions in children with multiple sclerosis.

Neurology·2011
Same author

Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

Cerebral cortex (New York, N.Y. : 1991)·2011
Same author

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

European journal of neurology·2011
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
Same journal

Functional movement disorders: diagnosis, pathophysiology, and treatment.

Current opinion in neurology·2026
Same journal

Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities: Erratum.

Current opinion in neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Endocrinology
  • Gastroenterology

Background:

  • Diabetic peripheral neuropathy affects one-third of diabetic patients.
  • Autonomic dysfunction is prevalent in nonalcoholic chronic liver disease.
  • Pathogenesis of metabolic neuropathy, including immunologic factors, remains unclear.

Purpose of the Study:

  • To review the epidemiology and predictors of diabetic polyneuropathy.
  • To discuss the role of autonomic dysfunction in liver disease.
  • To explore potential therapeutic strategies for diabetic neuropathy.

Main Methods:

  • Epidemiological data analysis.
  • Literature review of neuropathy pathogenesis and treatment.
  • Case study of pancreas-kidney transplantation outcomes.

Related Experiment Videos

Main Results:

  • Diabetes duration, poor glycemic control, smoking, and hypertension are independent predictors of diabetic polyneuropathy.
  • Successful pancreas-kidney transplantation ameliorated peripheral nerve function.
  • No specific treatments are currently available for diabetic neuropathies.

Conclusions:

  • Metabolic derangement correction is fundamental for managing diabetic neuropathy.
  • Neurotrophins may offer future therapeutic potential.
  • Further research is needed to confirm treatment efficacy.